A. Alian, S. L. Griner, V. Chiang, M. Tsiang, G. Jones et al., Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs, Proceedings of the National Academy of Sciences, vol.106, issue.20, pp.8192-8199, 2009.
DOI : 10.1073/pnas.0811919106

D. Wang, M. F. Ellis, A. L. Becker, H. J. Lasut, D. R. George et al., Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy, Antimicrob Agents Chemother, vol.44, pp.2475-84, 2000.

C. A. Boucher, N. Cammack, P. Schipper, R. Schuurman, P. Rouse et al., High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase., Antimicrobial Agents and Chemotherapy, vol.37, issue.10, pp.2231-2235, 1993.
DOI : 10.1128/AAC.37.10.2231

N. Clementi and . Gianotti, Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies, AIDS, vol.23, pp.455-60, 2009.

F. Ceccherini-silberstein, I. Malet, R. D. Arrigo, A. Antinori, A. G. Marcelin et al., Characterization and structural analysis of HIV-1 integrase conservation, AIDS Rev, vol.11, pp.17-29, 2009.

C. Charpentier, D. E. Dwyer, F. Mammano, D. Lecossier, F. Clavel et al., Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors, Journal of Virology, vol.78, issue.8, pp.4234-4281, 2004.
DOI : 10.1128/JVI.78.8.4234-4247.2004

. Clavel##, Umbruchvorlage 06.11, pp.51-52, 2009.

J. M. Coffin, HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy, Science, vol.267, issue.5197, pp.483-492, 1995.
DOI : 10.1126/science.7824947

J. H. Condra, W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham et al., In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors, Nature, vol.374, issue.6522, pp.569-71, 1995.
DOI : 10.1038/374569a0

R. D. Dinubile, H. Isaacs, B. Y. Teppler, and . Nguyen, Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection, N Engl J Med, vol.359, pp.355-65, 2008.

O. Delelis, I. Malet, L. Na, L. Tchertanov, V. Calvez et al., The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation, Nucleic Acids Research, vol.37, issue.4, pp.1193-201, 2009.
DOI : 10.1093/nar/gkn1050

A. Depatureaux, M. Leoz, G. Le-moal, J. Pathé, J. Pavie et al., Raltegravir is effective in HIV-1 group O infected patients. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention:Cape Town, 2009.

I. Dierynck, M. De-wit, E. Gustin, I. Keuleers, J. Vandersmissen et al., Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier, Journal of Virology, vol.81, issue.24, pp.13845-51, 2007.
DOI : 10.1128/JVI.01184-07

J. Dolan, A. Chen, I. T. Weber, R. W. Harrison, and J. Leis, Defining the DNA Substrate Binding Sites on HIV-1 Integrase, Journal of Molecular Biology, vol.385, issue.2, pp.568-79, 2009.
DOI : 10.1016/j.jmb.2008.10.083

D. Esposito and R. Craigie, Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction, The EMBO Journal, vol.17, issue.19, pp.5832-5875, 1998.
DOI : 10.1093/emboj/17.19.5832

R. B. Ferns, S. Kirk, J. Bennett, I. Williams, S. Edwards et al., The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy, AIDS, vol.23, issue.16, pp.2159-64, 2009.
DOI : 10.1097/QAD.0b013e32832ec4ae

V. Fikkert, B. Van-maele, J. Vercammen, A. Hantson, B. Van-remoortel et al., Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations, Journal of Virology, vol.77, issue.21, pp.11459-70, 2003.
DOI : 10.1128/JVI.77.21.11459-11470.2003

S. Fransen, S. Gupta, R. Danovich, D. Hazuda, M. Miller et al., Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways, Journal of Virology, vol.83, issue.22, pp.11440-11446, 2009.
DOI : 10.1128/JVI.01168-09

S. Fransen, M. Karmochkine, W. Huang, L. Weiss, C. J. Petropoulos et al., Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure, Antimicrobial Agents and Chemotherapy, vol.53, issue.10, pp.4522-4526, 2009.
DOI : 10.1128/AAC.00651-09

K. Gao, S. L. Butler, and F. Bushman, Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes, The EMBO Journal, vol.20, issue.13, pp.3565-76, 2001.
DOI : 10.1093/emboj/20.13.3565

E. P. Garvey, B. A. Johns, M. J. Gartland, S. A. Foster, W. H. Miller et al., The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral, Antimicrobial Agents and Chemotherapy, vol.52, issue.3, pp.901-909, 2008.
DOI : 10.1128/AAC.01218-07

O. Goethals, R. Clayton, M. Van-ginderen, I. Vereycken, E. Wagemans et al., Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors, Journal of Virology, vol.82, issue.21, pp.10366-74, 2008.
DOI : 10.1128/JVI.00470-08

D. J. Hazuda, N. J. Anthony, R. P. Gomez, S. M. Jolly, J. S. Wai et al., A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase, Proceedings of the National Academy of Sciences, vol.101, issue.31, pp.11233-11241, 2004.
DOI : 10.1073/pnas.0402357101

D. J. Hazuda, P. Felock, M. Witmer, A. Wolfe, K. Stillmock et al., Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells, Science, vol.287, issue.5453, pp.646-50, 2000.
DOI : 10.1126/science.287.5453.646

D. D. Ho, A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard et al., Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature, vol.176, issue.6510, pp.123-129, 1995.
DOI : 10.1038/373123a0

T. M. Jenkins, D. Esposito, A. Engelman, and R. Craigie, Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking, The EMBO Journal, vol.16, issue.22, pp.6849-59, 1997.
DOI : 10.1093/emboj/16.22.6849

G. S. Jones, F. Yu, A. Zeynalzadegan, J. Hesselgesser, X. Chen et al., Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase, Antimicrobial Agents and Chemotherapy, vol.53, issue.3, pp.1194-203, 2009.
DOI : 10.1128/AAC.00984-08

A. H. Kaplan, S. F. Michael, R. S. Wehbie, M. F. Knigge, D. A. Paul et al., Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease., Proceedings of the National Academy of Sciences, vol.91, issue.12, pp.5597-601, 1994.
DOI : 10.1073/pnas.91.12.5597

M. Kobayashi, K. Nakahara, T. Seki, S. Miki, S. Kawauchi et al., Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants, Antiviral Research, vol.80, issue.2, pp.213-235, 2008.
DOI : 10.1016/j.antiviral.2008.06.012

J. L. Lennox, E. Dejesus, A. Lazzarin, R. B. Pollard, J. V. Madruga et al., Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, The Lancet, vol.374, issue.9692, pp.796-806, 2009.
DOI : 10.1016/S0140-6736(09)60918-1

A. Low, N. Prada, M. Topper, F. Vaida, D. Castor et al., Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors, Antimicrobial Agents and Chemotherapy, vol.53, issue.10, pp.4275-82, 2009.
DOI : 10.1128/AAC.00397-09

I. Malet, O. Delelis, C. Soulie, M. Wirden, L. Tchertanov et al., Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients, Journal of Antimicrobial Chemotherapy, vol.63, issue.4, pp.795-804, 2009.
DOI : 10.1093/jac/dkp014

I. Malet, O. Delelis, M. A. Valantin, B. Montes, C. Soulie et al., Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, pp.1351-1359, 2008.
DOI : 10.1128/AAC.01228-07

F. Mammano, V. Trouplin, V. Zennou, and F. Clavel, Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug, Journal of Virology, vol.74, issue.18, pp.8524-8555, 2000.
DOI : 10.1128/JVI.74.18.8524-8531.2000

L. Menendez-arias, Molecular basis of human immunodeficiency virus drug resistance: An update, Antiviral Research, vol.85, issue.1, 2009.
DOI : 10.1016/j.antiviral.2009.07.006

A. Meyerhans, R. Cheynier, J. Albert, M. Seth, S. Kwok et al., Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations, Cell, vol.58, issue.5, pp.901-911, 1989.
DOI : 10.1016/0092-8674(89)90942-2

A. Molla, M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper et al., Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nature Medicine, vol.69, issue.7, pp.760-766, 1996.
DOI : 10.1016/S0140-6736(95)90699-1

J. F. Mouscadet, R. Arora, J. Andre, J. C. Lambry, O. Delelis et al., HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations, Journal of Molecular Recognition, vol.52, issue.21, pp.480-94, 2009.
DOI : 10.1177/108705710275212

URL : https://hal.archives-ouvertes.fr/hal-00811679

R. E. Myers and D. Pillay, Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 Integrase, Journal of Virology, vol.82, issue.18, pp.9228-9263, 2008.
DOI : 10.1128/JVI.01535-07

T. Sato and . Fujiwara, Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics, Antiviral Res, vol.81, pp.141-147, 2009.

A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho, HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time, Science, vol.271, issue.5255, pp.1582-1588, 1996.
DOI : 10.1126/science.271.5255.1582

V. Perrin and F. Mammano, Parameters Driving the Selection of Nelfinavir-Resistant Human Immunodeficiency Virus Type 1 Variants, Journal of Virology, vol.77, issue.18, pp.10172-10177, 2003.
DOI : 10.1128/JVI.77.18.10172-10175.2003

B. D. Preston, B. J. Poiesz, and L. A. Loeb, Fidelity of HIV-1 reverse transcriptase, Science, vol.242, issue.4882, pp.1168-71, 1988.
DOI : 10.1126/science.2460924

R. Quercia, E. Dam, D. Perez-bercoff, and F. Clavel, Selective-Advantage Profile of Human Immunodeficiency Virus Type 1 Integrase Mutants Explains In Vivo Evolution of Raltegravir Resistance Genotypes, Journal of Virology, vol.83, issue.19, pp.10245-10254, 2009.
DOI : 10.1128/JVI.00894-09

D. D. Richman, D. Havlir, J. Corbeil, D. Looney, C. Ignacio et al., Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy, J Virol, vol.68, pp.1660-1666, 1994.

J. D. Roberts, K. Bebenek, and T. A. Kunkel, The accuracy of reverse transcriptase from HIV-1, Science, vol.242, issue.4882, pp.1171-1174, 1988.
DOI : 10.1126/science.2460925

M. Salgado, C. Toro, A. Simon, C. Garrido, F. Blanco et al., Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity, Journal of Clinical Virology, vol.46, issue.2, pp.173-178, 2009.
DOI : 10.1016/j.jcv.2009.06.020

E. Serrao, S. Odde, K. Ramkumar, and N. Neamati, Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors, Retrovirology, vol.6, issue.1, p.25, 2009.
DOI : 10.1186/1742-4690-6-25

K. Shimura, E. Kodama, Y. Sakagami, Y. Matsuzaki, W. Watanabe et al., Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137), Journal of Virology, vol.82, issue.2, pp.764-74, 2008.
DOI : 10.1128/JVI.01534-07

N. Sichtig, S. Sierra, R. Kaiser, M. Daumer, S. Reuter et al., Evolution of raltegravir resistance during therapy, Journal of Antimicrobial Chemotherapy, vol.64, issue.1, pp.25-32, 2009.
DOI : 10.1093/jac/dkp153

R. D. Dinubile, B. Y. Isaacs, H. Nguyen, and . Teppler, Raltegravir with optimized background therapy for resistant HIV-1 infection, N Engl J Med, vol.359, pp.339-54, 2008.

M. Underwood, B. Johns, A. Sato, T. Fujiwara, and W. Spreen, S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention:Cape Town, 2009.

K. Van-baelen, V. Van-eygen, E. Rondelez, and L. J. Stuyver, Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility, AIDS, vol.22, issue.14, pp.1877-80, 2008.
DOI : 10.1097/QAD.0b013e32830f9703

J. Vingerhoets, H. Azijn, E. Fransen, I. De-baere, L. Smeulders et al., TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments, Journal of Virology, vol.79, issue.20, pp.12773-82, 2005.
DOI : 10.1128/JVI.79.20.12773-12782.2005

M. Westby, C. Smith-burchnell, J. Mori, M. Lewis, M. Mosley et al., Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry, Journal of Virology, vol.81, issue.5, pp.2359-71, 2007.
DOI : 10.1128/JVI.02006-06

L. Xu, J. Anderson, B. Ferns, P. Cook, A. Wildfire et al., Genetic Diversity of Integrase (IN) Sequences in Antiretroviral Treatment-Naive and Treatment-Experienced HIV Type 2 Patients, AIDS Research and Human Retroviruses, vol.24, issue.7, pp.1003-1010, 2008.
DOI : 10.1089/aid.2007.0303

M. D. Address-for-correspondence:-françois-clavel, Inserm U941 Institut Universitaire d'Hématologie Hôpital Saint-Louis Paris France E-mail: francois.clavel@inserm, fr EUROPEAN JOURNAL OF MEDICAL RESEARCH, vol.54, 2009.